Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase

被引:137
作者
Babaoglu, Kerim [2 ]
Simeonov, Anton [1 ]
Lrwin, John J. [2 ]
Nelson, Michael E. [1 ]
Feng, Brian [2 ]
Thomas, Craig J. [1 ]
Cancian, Laura [4 ]
Costi, M. Paola [4 ]
Maltby, David A. [3 ]
Jadhav, Ajit [1 ]
Inglese, James [1 ]
Austin, Christopher P. [1 ]
Shoichet, Brian K. [2 ]
机构
[1] NHGRI, Chem Genom Ctr, NIH, Bethesda, MD 20892 USA
[2] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA
[3] Univ Calif San Francisco, Dept Pharmaceut Chem, Mass Spect Facil, San Francisco, CA 94143 USA
[4] Univ Modena & Reggio Emilia, Dipartimento Sci Farmaceut, I-41100 Modena, Italy
关键词
D O I
10.1021/jm701500e
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
High-throughput screening (HTS) is widely used in drug discovery. Especially for screens of unbiased libraries, false positives can dominate "hit lists"; their origins are much debated. Here we determine the mechanism of every active hit from a screen of 70,563 unbiased molecules against P-lactamase using quantitative HTS (qHTS). Of the 1274 initial inhibitors, 95% were detergent- sensitive and were classified as aggregators. Among the 70 remaining were 25 potent, covalent-acting beta-lactams. Mass spectra, counter-screens, and crystallography identified 12 as promiscuous covalent inhibitors. The remaining 33 were either aggregators or irreproducible. No specific reversible inhibitors were found. We turned to molecular docking to prioritize molecules from the same library for testing at higher concentrations. Of 16 tested, 2 were modest inhibitors. Subsequent X-ray structures corresponded to the docking prediction. Analog synthesis improved affinity to 8 mu M. These results suggest that it may be the physical behavior of organic molecules, not their reactivity, that accounts for most screening artifacts. Structure-based methods may prioritize weak-but-novel chemotypes in unbiased library screens.
引用
收藏
页码:2502 / 2511
页数:10
相关论文
共 49 条
  • [1] Deconstructing fragment-based inhibitor discovery
    Babaoglu, Kerim
    Shoichet, Brian K.
    [J]. NATURE CHEMICAL BIOLOGY, 2006, 2 (12) : 720 - 723
  • [2] The deacylation mechanism of AmpC β-lactamase at ultrahigh resolution
    Chen, Y
    Minasov, G
    Roth, TA
    Prati, F
    Shoichet, BK
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (09) : 2970 - 2976
  • [3] Coot:: model-building tools for molecular graphics
    Emsley, P
    Cowtan, K
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2004, 60 : 2126 - 2132
  • [4] Fragment-based drug discovery
    Erlanson, DA
    McDowell, RS
    O'Brien, T
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (14) : 3463 - 3482
  • [5] Tethering: Fragment-based drug discovery
    Erlanson, DA
    Wells, JA
    Braisted, AC
    [J]. ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE, 2004, 33 : 199 - 223
  • [6] A high-throughput screen for aggregation-based inhibition in a large compound library
    Feng, Brian Y.
    Simeonov, Anton
    Jadhav, Ajit
    Babaoglu, Kerim
    Inglese, James
    Shoichet, Brian K.
    Austin, Christopher P.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (10) : 2385 - 2390
  • [7] High-throughput assays for promiscuous inhibitors
    Feng, BY
    Shelat, A
    Doman, TN
    Guy, RK
    Shoichet, BK
    [J]. NATURE CHEMICAL BIOLOGY, 2005, 1 (03) : 146 - 148
  • [8] Evaluating real-life high-throughput screening data
    Gribbon, P
    Lyons, R
    Laflin, P
    Bradley, J
    Chambers, C
    Williams, BS
    Keighley, W
    Sewing, A
    [J]. JOURNAL OF BIOMOLECULAR SCREENING, 2005, 10 (02) : 99 - 107
  • [9] Grüneberg S, 2001, ANGEW CHEM INT EDIT, V40, P389, DOI 10.1002/1521-3773(20010119)40:2<389::AID-ANIE389>3.0.CO
  • [10] 2-#